respekt 75 mg/1 tableta film tableta
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - klopidogrel - film tableta - 75 mg/1 tableta - 1 film tableta sadrži: 75 mg klopidogrel (u obliku klopidogrelbisulfata)
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - ostali srčani pripravci - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
farcet 75 mg filmom obložene tablete
adamed sp. z o.o., pienków 149, czosnów, poljska - clopidogrelum - filmom obložena tableta - 75 mg - urbroj: jedna filmom obložena tableta sadrži 75 mg klopidogrela u obliku klopidogrelhidrogensulfata
pigrel 75 mg filmom obložene tablete
jadran galenski laboratorij d.d., svilno 20, rijeka, hrvatska - klopidogrelhidrogensulfat - filmom obložena tableta - 75 mg - urbroj: 1 filmom obložena tableta sadrži 75 mg klopidogrela u obliku klopidogrel hidrogensulfata
cardogrel 75 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - klopidogrel - filmom obložena tableta - 75 mg/1 tableta - 1 filmom obložena tableta sadrži: 75 mg klopidogrel (u obliku klopidogrelhidrogensulfata)
clodil 75 mg/1 tableta film tableta
bosnalijek d.d. - klopidogrel - film tableta - 75 mg/1 tableta - 1 film tableta sadrži: 75 mg klopidogrel (u obliku klopidogrelhidrogensulfata)
pigrel 75 mg/1 tableta filmom obložena tableta
farmis d.o.o. - klopidogrel - filmom obložena tableta - 75 mg/1 tableta - 1 filmom obložena tableta sadrži: 75 mg klopidogrel (u obliku klopidogrelhidrogensulfata)
synetra 75 mg/1 tableta film tableta
alkaloid d.o.o. sarajevo - klopidogrel - film tableta - 75 mg/1 tableta - 1 film tableta sadrži: 75 mg klopidogrela (u obliku klopidogrelbisulfata)
attera 75 mg/1 tableta filmom obložena tableta
amsal pharmaceuticals d.o.o. - klopidogrel - filmom obložena tableta - 75 mg/1 tableta - 1 filmom obložena tableta sadrži: 75 mg klopidogrela
clopidogrel acino
acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotska sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.